Biomarker analysis in patients enrolled in the RESORCE trial has shown that plasma levels of angiopoietin 1, which promotes tumor proliferation and angiogenesis, are prognostic in patients treated with regorafenib but not in the overall population [57]. This evidence concerns the gene ANGPT1 and neoplasm.